Korro Bio (NASDAQ:KRRO - Get Free Report) is anticipated to release its Q4 2024 earnings data before the market opens on Tuesday, March 18th. Analysts expect Korro Bio to post earnings of ($2.33) per share for the quarter.
Korro Bio (NASDAQ:KRRO - Get Free Report) last announced its earnings results on Tuesday, March 18th. The company reported ($2.26) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($2.33) by $0.07. The company had revenue of $2.27 million for the quarter. On average, analysts expect Korro Bio to post $-10 EPS for the current fiscal year and $-10 EPS for the next fiscal year.
Korro Bio Stock Up 9.0 %
NASDAQ:KRRO traded up $1.98 during trading hours on Friday, hitting $23.88. 49,471 shares of the company's stock traded hands, compared to its average volume of 87,287. Korro Bio has a twelve month low of $18.50 and a twelve month high of $98.00. The stock's fifty day moving average price is $30.11 and its two-hundred day moving average price is $41.56.
Wall Street Analyst Weigh In
Several research analysts have weighed in on the company. Oppenheimer assumed coverage on Korro Bio in a research report on Friday, January 10th. They issued an "outperform" rating and a $155.00 target price on the stock. HC Wainwright reaffirmed a "buy" rating and issued a $115.00 target price on shares of Korro Bio in a research report on Thursday. Finally, Royal Bank of Canada dropped their target price on Korro Bio from $105.00 to $95.00 and set an "outperform" rating on the stock in a research report on Wednesday. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of "Buy" and an average price target of $142.57.
Read Our Latest Stock Analysis on KRRO
Korro Bio Company Profile
(
Get Free Report)
Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).
Recommended Stories
Before you consider Korro Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Korro Bio wasn't on the list.
While Korro Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
